Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Prefoldin subunit 2 (PFDN2) is a beta subunit of the prefoldin complex, a heterohexameric molecular chaperone that binds and stabilizes newly synthesized polypeptides—primarily actin and tubulin—to ensure proper folding and prevent aggregation. The prefoldin complex facilitates the transfer of these polypeptides to the cytosolic chaperonin TCP-1/TRiC/CCT for final folding steps, crucial for cytoskeletal maintenance and protein homeostasis. PFDN2, along with other subunits, is evolutionarily conserved and important for cellular processes such as mitosis, neuronal development, and cellular stress responses. Alterations in PFDN2 expression or function have been associated with disease states including various cancers and neurodegenerative conditions due to its role in protein folding and prevention of aggregation. There is currently no evidence that PFDN2 is a direct pharmacological target, nor are there established biomarkers or safety concerns specific to its modulation in therapy.
Not applicable (as there are no drugs targeting this molecule)
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Prefoldin subunit 2 (PFDN2).